

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

---

In re Patent Application of:  
Mladen Mercep et al.

Application No.: National Phase of  
PCT/HR2004/000054

Confirmation No.: N/A

Filed: Concurrently Herewith

Art Unit: N/A

For: 3-AZA-1-OXA-DIBENZO[E,H]AZULENES  
FOR THE TREATMENT OF CENTRAL  
NERVOUS SYSTEM DISEASES AND  
DISORDERS

---

Examiner: Not Yet Assigned

**FIRST PRELIMINARY AMENDMENT**

MS Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Dear Sir:

**INTRODUCTORY COMMENTS**

Prior to examination on the merits, please amend the above-identified U.S. patent application as follows:

**Amendments to the Specification** begin on page 2 of this paper.

**Amendments to the Claims** are reflected in the listing of claims which begins on page 3 of this paper.

**Amendments to the Abstract** begin on page 10 of this paper.

**Remarks/Arguments** begin on page 11 of this paper.